Allergan wins patent dispute over generic Alphagan

10/25/2009 | MarketWatch

A federal court in Wilmington, Del., has sided with Allergan in its patent lawsuit against Exela and Apotex over eye drug Alphagan. As a result, the generic-drug firms will not be able to launch their versions of the product, a treatment for open-angle glaucoma and ocular hypertension, until Alphagan's patents expire in 2022.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY